Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017 (2017), Article ID 6162845, 7 pages
https://doi.org/10.1155/2017/6162845
Clinical Study

A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma

1CHU of Liege, Nuclear Medicine and Oncological Imaging Division, Medical Physics Department, Liege, Belgium
2CHU of Liege, Department of Clinical Hematology, Liege, Belgium
3Molecular Imaging Program at Stanford (MIPS), Radiology Department, Stanford University, Stanford, CA, USA

Correspondence should be addressed to Jo Caers; eb.ca.glu.uhc@sreac.oj

Received 19 March 2017; Revised 15 May 2017; Accepted 13 June 2017; Published 27 July 2017

Academic Editor: Xuelei Ma

Copyright © 2017 Nadia Withofs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. V. Rajkumar, M. A. Dimopoulos, and A. Palumbo, “International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma,” The Lancet Oncology, vol. 15, no. 12, pp. e538–e548, 2014. View at Publisher · View at Google Scholar
  2. J. Caers, C. F. De Larrea, X. Leleu et al., “The changing landscape of smoldering multiple myeloma: a european perspective,” Oncologist, vol. 21, no. 3, pp. 333–342, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Cavo, E. Terpos, C. Nanni et al., “Role of F18-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group,” The Lancet Oncology, vol. 18, no. 4, pp. e206–e217, 2017. View at Publisher · View at Google Scholar
  4. Z. Wu, Z.-B. Li, W. Cai et al., “F18-labeled mini-PEG spacered RGD dimer (F18-FPRGD2): synthesis and microPET imaging of αvβ3 integrin expression,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 11, pp. 1823–1831, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Thonon, D. Goblet, E. Goukens et al., “Fully automated preparation and conjugation of N-succinimidyl 4-[F18]fluorobenzoate ([F18]SFB) with RGD peptide using a GE FASTlab synthesizer,” Molecular Imaging and Biology, vol. 13, no. 6, pp. 1088–1095, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Withofs, E. Charlier, P. Simoni et al., “F18-FPRGD2 PET/CT imaging of musculoskeletal disorders,” Annals of Nuclear Medicine, vol. 29, no. 10, pp. 839–847, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Withofs, N. Signolle, J. Somja et al., “18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology,” Journal of Nuclear Medicine, vol. 56, no. 3, pp. 361–364, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Withofs, P. Martinive, J. Vanderick et al., “[F18]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 4, pp. 654–662, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Haubner, HJ. Wester, U. Reuning, R. Senekowitsch-Schmidtke, B. Diefenbach, and H. Kessler, “Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting,” Journal of Nuclear Medicine, pp. 40–1061, 1999. View at Google Scholar
  10. S. M. Weis and D. A. Cheresh, “αv integrins in angiogenesis and cancer,” Cold Spring Harbor perspectives in medicine, vol. 1, no. 1, p. a006478, 2011. View at Google Scholar · View at Scopus
  11. F. C. Gaertner, H. Kessler, H.-J. Wester, M. Schwaiger, and A. J. Beer, “Radiolabelled RGD peptides for imaging and therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 1, pp. S126–S138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Seguin, J. S. Desgrosellier, S. M. Weis, and D. A. Cheresh, “Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance,” Trends in Cell Biology, vol. 25, no. 4, pp. 234–240, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. T. J. Wadas, H. Deng, J. E. Sprague, A. Zheleznyak, K. N. Weilbaecher, and C. J. Anderson, “Targeting the αvβ3 integrin for small-animal PET/CT of osteolytic bone metastases,” Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1873–1880, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Cohen, N. Flint, S. Shalev et al., “Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells,” Oncotarget, vol. 5, no. 15, pp. 6312–6322, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Stucci, M. Tucci, A. Passarelli, and F. Silvestris, “αvβ3 integrin: Pathogenetic role in osteotropic tumors,” Critical Reviews in Oncology/Hematology, vol. 96, no. 1, pp. 183–193, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. J. G. Schneider, S. R. Amend, and K. N. Weilbaecher, “Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions,” Bone, vol. 48, no. 1, pp. 54–65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Caers, U. Günthert, H. De Raeve et al., “The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model,” British Journal of Haematology, vol. 132, no. 4, pp. 469–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Iagaru, E. Mittra, S. S. Yaghoubi et al., “Novel strategy for a cocktail F18-fluoride and F18-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study,” Journal of Nuclear Medicine, vol. 50, no. 4, pp. 501–505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. C. Sampath, S. C. Sampath, C. Mosci et al., “Detection of osseous metastasis by F18-NaF/F18-FDG PET/CT versus CT alone,” Clinical Nuclear Medicine, vol. 40, no. 3, pp. e173–e177, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Withofs, F. Cousin, T. Tancredi, Simoni P., De Prijck B., Hafraoui K. et al., “Comparison of combined whole-body [F18]NaF and [F18]FDG PET/CT versus MRI for the detection of myeloma lesions,” Journal of Nuclear Medicine, vol. 57, supplement 2, article 606, 2016. View at Google Scholar
  21. C. Sachpekidis, J. Hillengass, H. Goldschmidt et al., “Treatment response evaluation with F18-FDG PET/CT and F18-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 1, pp. 50–62, 2017. View at Publisher · View at Google Scholar
  22. E. Otjacques, M. Binsfeld, A. Noel, Y. Beguin, D. Cataldo, and J. Caers, “Biological aspects of angiogenesis in multiple myeloma,” International Journal of Hematology, vol. 94, no. 6, pp. 505–518, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Rasche, E. Angtuaco, J. E. McDonald et al., “Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma,” Blood, vol. 130, no. 1, pp. 30–34, 2017. View at Publisher · View at Google Scholar
  24. M. Tucci, S. Stucci, C. Felici et al., “Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells,” British Journal of Haematology, vol. 173, no. 1, pp. 59–69, 2016. View at Publisher · View at Google Scholar · View at Scopus